Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €32.00 EUR
Change Today -0.77 / -2.36%
Volume 0.0
As of 11:01 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

merck kgaa-unsponsored adr (MRKA) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/13/15 - €37.40
52 Week Low
07/1/14 - €10.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

merck kgaa-unsponsored adr (MRKA) Related Businessweek News

No Related Businessweek News Found

merck kgaa-unsponsored adr (MRKA) Details

Merck Kommanditgesellschaft auf Aktien discovers, develops, manufactures, and markets pharmaceutical and chemical products worldwide. The company provides pharmaceutical and biological prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and cardiovascular and metabolic diseases; fertility drugs for every stage of the reproductive cycle; hypoallergenic products for specific immunotherapy and diagnosis of type 1 allergies; and biosimilars focusing on oncology and inflammatory disorders. It also manufactures and markets over-the-counter pharmaceuticals to address mobility, women’s and children’s health, cough and cold, and everyday health protection under the Neurobion, Bion, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brand names. In addition, the company offers life science tools and technologies for use in the research, development, and manufacture of biotechnological and pharmaceutical drug therapies, as well as in research and application laboratories. Further, it provides specialty chemicals that are used in various end products, including liquid crystals for displays; LED materials for lighting, as well as organic light-emitting diode materials for lighting and displays; functional materials for solar panels and energy solutions; effect pigments, as well as active ingredients and fillers for cosmetics, food, and pharmaceutical products; pigments and functional materials for coatings, printing, and plastics; and specialty chemical materials for the electronics industry. The company has a strategic alliance with Pfizer Inc. to develop and commercialize active ingredients in immuno-oncology; and strategic immuno-oncology collaboration with MorphoSys to discover and develop therapeutic antibodies against immune checkpoints. Merck Kommanditgesellschaft auf Aktien was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

39,842 Employees
Last Reported Date: 05/19/15
Founded in 1668

merck kgaa-unsponsored adr (MRKA) Top Compensated Officers

Chairman of Executive Board and Chief Executi...
Total Annual Compensation: €6.6M
Group Chief Financial Officer and Member of E...
Total Annual Compensation: €1.2M
Chief Executive Officer of Life Science & Per...
Total Annual Compensation: €4.7M
Vice Chairman of Executive Board and Deputy C...
Total Annual Compensation: €6.0M
Head of Group Human Resources, General Partne...
Total Annual Compensation: €4.0M
Compensation as of Fiscal Year 2014.

merck kgaa-unsponsored adr (MRKA) Key Developments

Merck KGaA Announces Group Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Fiscal 2015

Merck KGaA announced earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported operating result (EBIT) was EUR 480.0 million against EUR 468.3 million a year ago. EBITDA was EUR 805.4 million against EUR 770.2 million a year ago. Earnings per share were EUR 0.65 against EUR 0.75 a year ago. Earnings per share pre-exceptional were EUR 1.12 against EUR 1.15 a year ago. Net income was EUR 281.7 million against EUR 325.2 million a year ago. Net financial debt as at March 31, 2015 was EUR 78 million against EUR 559 million as at December 31, 2014. Core earnings increased 5.7% on the year but missed expectations due to higher marketing and research costs. Earnings before interest, taxes, depreciation and amortization (EBITDA), excluding one-off items, rose to EUR 853 million (USD 963 million) in the first three months of the year. Revenue climbed 16% to EUR 3.04 billion. Earnings were affected by higher immuno-oncology research spending, higher marketing and selling expenses as well as the absence of royalty and license income that had already expired in the second quarter of 2014. For the year 2015, Merck continues to expect slight organic sales growth and a slight portfolio effect due to the inclusion of AZ for a full fiscal year. This development will be supported by strong, positive foreign exchange effects. Overall, Merck assumes an increase in net sales to between EUR 12.3 billion and EUR 12.5 billion in 2015. The company anticipates EBITDA pre exceptionals of between EUR 3.45 billion and EUR 3.55 billion in 2015 despite higher R&D spending in the Healthcare business sector, the downturn in the development of Rebif in the United States and Europe, as well as the absence of royalty and license income. Business free cash flow of the Merck Group is expected to lie between EUR 2.4 billion and EUR 2.5 billion in 2015. Sales are expected to increase only slightly.

Merck KGaA Receives FDA Fast Track Designation for evofosfamide for the Treatment of Patients Living with Advanced Pancreatic Cancer

Threshold Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company's partner Merck KGaA, for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer. This is the second Fast Track designation for evofosfamide, the first having been granted to Threshold in November 2014 for the development of evofosfamide in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma. Threshold and Merck KGaA, Darmstadt, Germany, are collaborating on the development of evofosfamide, an investigational compound currently in Phase 3 clinical trials.

Merck Millipore Introduces Magna ChIRP RNA Interactome Kits

Merck Millipore introduced Magna ChIRP RNA Interactome Kits, which allow researchers to more easily identify, recover and analyze regions of chromatin that interact with chromatin-associated RNAs such as long non-coding RNA (lncRNA). The highly effective multiprobe-based capture strategy uses cross-linked chromatin to provide reliable detection and discovery of RNA-associated genomic DNA sequences, RNA sequences and proteins. The new kits use the ChIRP method (Chromatin Isolation by RNA Purification) to isolate chromatin complexes using RNA as the target, allowing researchers to pinpoint specific sites of genomic interaction for chromatin-associated RNAs. The kits simplify the ChIRP method, providing all necessary buffers, enzymes and reagents in one validated kit, as well as a negative control probe set and detailed protocol with capture probe design guidelines. In addition, first-time users can opt for the EZ-Magna ChIRP kit, which includes a positive control capture probe set and detection primers that make it easier to validate an experiment's success.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRKA:GR €32.00 EUR -0.77

MRKA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akzo Nobel NV €69.35 EUR -1.50
Johnson Matthey PLC 3,499 GBp -72.00
Solvay SA €126.00 EUR -2.20
UCB SA €65.10 EUR +0.46
Yara International ASA 392.20 NOK +1.00
View Industry Companies

Industry Analysis


Industry Average

Valuation MRKA Industry Range
Price/Earnings 39.0x
Price/Sales 3.6x
Price/Book 3.2x
Price/Cash Flow 11.6x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK KGAA-UNSPONSORED ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at